Prognostic role of serum cytokines in patients with nasopharyngeal carcinoma

Onkologie

Volumn 35, Issue 9, 2012, Pages 494-498

  Lu, Ke ^a   Feng, Xinglai ^a   Deng, Qinghua ^a   Sheng, Liming ^a   Liu, Peng ^a   Xu, Shenhua ^b   Su, Dan ^b  

^a Department of Radiation Therapy ^*  (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Cytokine; Nasopharyngeal carcinoma; Prognosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; CHINA; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866859114     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000341827     Document Type: Article

References (32)

1. Erkal HS, Serin M, Cakmak A: Nasopharyngeal carcinomas: analysis of patient, tumor and treatment characteristics determining outcome. Radiother Oncol 2001;61:247-56.
2. Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY: Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005;62:672-9.
3. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, Kwong DL, Lau WH: Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005;61:1107-16.
4. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009;27:3684-90.
5. Guigay J: Advances in nasopharyngeal carcinoma. Curr Opin Oncol 2008;20:264-9.
6. Leung TW, Tung SY, Sze WK, Wong FC, Yuen KK, Lui CM, Lo SH, Ng TY, O SK: Treatment results of 1,070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck 2005;27:555-65.
7. Kwong D, Sham J, Choy D: The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx: an analysis of 1,301 patients. Int J Radiat Oncol Biol Phys 1994;30:1029-36.
8. Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, Guo Y, Huang YJ, Guan ZZ: The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 2010;10:558.
9. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860-7.
10. Rollins BJ: Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006;42:760-7.
11. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, Chan KC, Chan LY, Kwan WH, Lo YM, Chan AT: Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006;24:5414-8.
12. Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M: A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK-and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 2010;116:3695-704.
13. De Leo A, Matusali G, Arena G, Di Renzo L, Mattia E: Epstein-Barr virus lytic cycle activation alters proteasome subunit expression in Burkitt's lymphoma cells. Biol Chem 2010;391:1041-6.
14. Pistoia V, Bianchi G, Borgonovo G, Raffaghello L: Cytokines in neuroblastoma: from pathogenesis to treatment. Immunotherapy 2011;3:895-907.
15. Yoshino S, Tabata T, Hazama S, Iizuka N, Yamamoto K, Hirayama M, Tangoku A, Oka M: Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res 2000;20: 4707-11.
16. Lauerova L, Dusek L, Simickova M, Kocák I, Vagundová M, Zaloudík J, Kovarík J: Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002;49:159-66.
17. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep 2006;15:1513-6.
18. Weifeng Q, Bingyu X, Shenhua X, Weixian S, Gianxi Z, Yuanda Z: An analysis of 6 kinds of cytokine in peripheral blood in 207 cases with nasopharyngeal cancer. J Oncol (Chinese) 2005;11:349-50.
19. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
20. Chang KP, Chang YT, Wu CC, Liu YL, Chen MC, Tsang NM, Hsu CL, Chang YS, Yu JS: Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 2011;33: 886-97.
21. Lu X, Qian CN, Mu YG, Li NW, Li S, Zhang HB, Li SW, Wang FL, Guo X, Xiang YQ: Serum CCL2 and serum TNF-?-two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. Eur J Cancer 2011;47:339-46.
22. Zhou H, Huang H, Shi J, Zhao Y, Dong Q, Jia H, Liu Y, Ye Q, Sun H, Zhu X, Fu L, Guo K, Gao D, Sun J, Yan Z, Ren N, Tang Z, Qin L: Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection. Gut 2010;59:1699-708.
23. Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, De Cataldis G, Catalano G: Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 2000;49:530-6.
24. Zhang Y, Luo CL, He BC, Zhang JM, Cheng G, Wu XH: Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int J Oncol 2010;36:133-40.
25. Kemp RA, Bäckström BT, Ronchese F: The phenotype of type 1 and type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity. Immunology 2005;115:315-24.
26. Jacobs JJ, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CH, Koten JW, Battermann JJ, Den Otter W: Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 2005;54:792-8.
27. Wu Y, Zhou BP: TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010;102:639-44.
28. Cui LF, Guo XJ, Wei J, Liu FF, Fan Y, Lang RG, Gu F, Zhang XM, Fu L: Overexpression of TNFalpha and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations. Histopathology 2008;53:381-8.
29. Hsiao SH, Lee MS, Lin HY, Su YC, Ho HC, Hwang JH, Lee CC, Hung SK: Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma. Acta Otolaryngol 2009;129:1519-23.
30. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T, Taffurelli M, Ceccarelli C, Santini D, Chieco P, Marcu KB, Bonafè M: TNFalpha upregulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 2010;225:682-91.
31. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Melfi F, Mussi A, Basolo F, Fontanini G: Tumour necrosis factor-alpha: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Int J Mol Med 2006;17:887-92.
32. Xu L, Pan J, Wu J, Pan C, Zhang Y, Lin S, Yang L, Chen C, Zhang C, Zheng W, Lin S, Ni X, Kong FM: Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. Radiother Oncol 2010; 96:94-9.